Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer

Int J Cancer. 2017 Mar 1;140(5):1173-1185. doi: 10.1002/ijc.30493. Epub 2016 Dec 2.

Abstract

SRC family kinases (SFKs), a group of nonreceptor tyrosine kinases, modulate multiple cellular functions, such as cell proliferation, differentiation and metabolism. SFKs display aberrant activity in progressive stages of human cancers. However, the precise role of SFKs in the head and neck squamous cell carcinoma (HNSCC) signaling network is far from clear. In this study, we found that the inhibition of SFKs activity by dasatinib effectively reduced the tumor size and population of MDSCs in the HNSCC mouse model. Molecular analysis indicates that phosphorylation of LYN, rather than SRC, was inhibited by dasatinib treatment. Next, we analyzed LYN expression by immunostaining and found that it was overexpressed in the human HNSCC specimens. Moreover, LYN expression in stromal cells positively correlated with myeloid-derived suppressor cells (MDSCs) makers CD11b and CD33 in human HNSCC. The dual positive expression of LYN in epithelial and stromal cells (EPI+ SRT+ ) was associated with unfavorable overall survival of HNSCC patients. These findings indicate that SFKs may be a potential target for an effective immunotherapy of HNSCC by decreasing MDSCs and moreover, LYN will have an impact on such therapeutic strategy.

Keywords: LYN kinase; SRC family kinase; head and neck cancer; myeloid-derived suppressor cell.

MeSH terms

  • Animals
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / enzymology
  • Carcinoma, Squamous Cell / immunology
  • Carcinoma, Squamous Cell / pathology*
  • Dasatinib / pharmacology
  • Dasatinib / therapeutic use*
  • Enzyme Induction / drug effects
  • Epithelial Cells / enzymology
  • Gene Expression Regulation, Neoplastic / drug effects
  • Head and Neck Neoplasms / drug therapy
  • Head and Neck Neoplasms / enzymology
  • Head and Neck Neoplasms / immunology
  • Head and Neck Neoplasms / pathology*
  • Humans
  • Mice
  • Mice, Knockout
  • Molecular Targeted Therapy
  • Myeloid-Derived Suppressor Cells / pathology*
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / physiology
  • PTEN Phosphohydrolase / deficiency
  • Phosphorylation / drug effects
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein Processing, Post-Translational / drug effects
  • Protein Serine-Threonine Kinases / deficiency
  • Receptor, Transforming Growth Factor-beta Type I
  • Receptors, Transforming Growth Factor beta / deficiency
  • Stromal Cells / enzymology
  • Tumor Escape
  • Up-Regulation
  • Xenograft Model Antitumor Assays
  • src-Family Kinases / antagonists & inhibitors*
  • src-Family Kinases / biosynthesis
  • src-Family Kinases / genetics
  • src-Family Kinases / metabolism
  • src-Family Kinases / physiology

Substances

  • Neoplasm Proteins
  • Protein Kinase Inhibitors
  • Receptors, Transforming Growth Factor beta
  • lyn protein-tyrosine kinase
  • src-Family Kinases
  • Protein Serine-Threonine Kinases
  • Receptor, Transforming Growth Factor-beta Type I
  • PTEN Phosphohydrolase
  • Pten protein, mouse
  • Dasatinib